Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
about
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisAtherosclerosis in psoriatic disease: latest evidence and clinical implicationsOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPutting together the psoriasis puzzle: an update on developing targeted therapiesUstekinumab in treatment of Crohn's disease: design, development, and potential place in therapyUstekinumab in Crohn's disease: evidence to date and place in therapyManagement of cardiovascular disease in patients with psoriasis.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.Biologic safety in psoriasis: review of long-term safety data.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.Risk of cardiovascular disorders in psoriasis patients: current and future.Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis.Preclinical development of AMG 139, a human antibody specifically targeting IL-23Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan.The impact of psoriasis on 10-year Framingham risk.Adaptive immunity in atherogenesis: new insights and therapeutic approaches.Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to dateAntipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein functionCombined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report.Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies.Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritisUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.Psoriasis comorbidities: complications and benefits of immunobiological treatmentComorbidities in Patients with Psoriatic Arthritis.Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.The concept of psoriasis as a systemic inflammation: implications for disease management.Current investigational drugs in psoriasis.Biologics in oral medicine: principles of use and practical considerations.Sequential use of biologics in moderate-to-severe plaque psoriasis: case studies illustrating an individualized approach.Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.Control of inflammatory heart disease by CD4+ T cells.Burden of disease: psoriasis and psoriatic arthritis.Biological therapies for psoriasis.Treating moderate to severe psoriasis - best use of biologics.Does treatment of psoriasis reduce the risk of cardiovascular disease?
P2860
Q26771682-73A94C55-DB2B-44D1-B73C-703F3317F9E5Q26783501-6AD0B65A-BA7B-4CFF-9B86-5405CA1351E7Q26827714-AF9D9AAB-2AE1-4257-8917-95A17AF0A285Q27026785-D708B0E1-660B-4793-A949-153F04A0A06AQ28067631-02A6ED35-98A2-44B5-81C6-C2616B3AA583Q28073787-79D9DACD-30CB-4ABD-8B82-4E6268E7EA59Q30250278-C4188D46-6933-48E2-8751-C759EC660BF2Q30574065-57623189-1DE0-4097-AA75-6755D264539AQ30577671-ACA7222F-4ACD-4750-B535-3D79BEB7B94BQ30904076-B9F96D48-D932-498D-9F36-443BB8F4463DQ33625546-4E9E6F7E-8955-4D81-8692-1BB0A6B56A43Q34189897-BE82AB1D-9935-44F1-B97B-239BFFB49AE7Q34323212-953C654C-E998-40A4-89A9-70AFF9941721Q34364602-E6ABB278-022D-4F7C-9573-E527D2AC3FBBQ34795742-59355C9C-432C-488E-ABA2-EC0D822A9A6FQ35606402-5A26DEC9-F624-4653-A05D-77536A8D54B5Q35860158-87275430-AE82-472E-AEC7-A9F2A7FDDB4FQ35934076-FA70923C-9E8A-4A2C-89E0-9FD3EAB8D1E9Q36240763-569568DA-AB16-4813-94AE-F4A818DC4845Q36497196-FC5356F1-EADB-4125-B8E3-DA7AC16A3494Q36643600-4F414E29-9F1C-486F-B610-ECEC21E6B511Q36681220-66CDEFF3-BFEA-4FB6-B224-6E308FF55FF6Q36714257-44DECD32-D2BB-413E-9528-A2027A8A53CEQ36824796-C31B196B-82DE-4AE8-B43F-EB637DD796D9Q36843650-3CCC7C77-53CE-402F-AEE7-FE7A46DDD7E1Q37258726-64804AAF-495D-48DF-9A21-CD743A49EC0DQ37540440-180F4DD8-CB36-4DE3-9C03-9DE5D4F0EBCAQ37632137-D5514097-2471-4FDD-BBC3-4C374F01792DQ37632485-63B49E34-EB58-400F-B43A-087D0D950376Q37980484-1C3C149B-7E49-4CEA-8630-6316A95FFEE6Q37987268-DF584CD8-8E23-44EA-A555-FF09FE2281A4Q37991748-ABA81E05-C4B6-4F2B-8EF2-16EB151671F5Q37993932-9E25B563-93A5-45E9-92D3-47581A30FB43Q38053456-C367C847-10E0-47C0-B6C1-B8A2C3989F14Q38091030-3E2CA563-E176-46CB-BE27-871B0F24BE57Q38108397-E33A14D3-98F3-4398-8BF2-F20B79600448Q38114850-45095BFE-D767-4A04-947A-FFC44ACF436CQ38155648-2199C50D-F795-4978-A753-62959350E5ACQ38174153-9DACA72A-4E9C-462E-AEB3-CCDF2ABB155EQ38178202-4EC15CBB-9487-428B-B076-6C0407B796F1
P2860
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Association between biologic t ...... randomized controlled trials.
@en
Association between biologic t ...... randomized controlled trials.
@nl
type
label
Association between biologic t ...... randomized controlled trials.
@en
Association between biologic t ...... randomized controlled trials.
@nl
prefLabel
Association between biologic t ...... randomized controlled trials.
@en
Association between biologic t ...... randomized controlled trials.
@nl
P2093
P50
P356
P1476
Association between biologic t ...... f randomized controlled trials
@en
P2093
Alan Menter
Craig L Leonardi
Dan H Kaplan
Derek Blankenship
James A de Lemos
James G Krueger
Kenneth B Gordon
Richard G Langley
Salahuddin Kazi
Vincent E Friedewald
P304
P356
10.1001/JAMA.2011.1211
P407
P577
2011-08-01T00:00:00Z